In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
July 24th, 2004 | 34 | Yes |
Popular Name: Loperamide hydrochloride Loperamide hydrochloride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 34552-83-5 , 34552-83-5, 53179-11-6 , 34552-83-5, 53179-11-6 [loperamide] , 53179-11-6 , [34552-83-5]
1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-.alpha.,.alpha.-diphenyl-
1-piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-a,a-diphenyl-, monohydrochloride
1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
34552-83-5; D00729; Imodium (TN); Loperamide hydrochloride (JAN/USP)
34552-83-5; Loperamide hydrochloride; Prestwick_302
4-(4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide hydrochloride
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6; C07080; Loperamide
53179-11-6; D08144; Diamide (TN); Loperamide (INN)
C29H33ClN2O2.C8H24O2Si3.Cl; IMODIUM ADVANCED; LOPERAMIDE HYDROCHLORIDE; SIMETHICONE; LS-178564
CPD000058466; Imodium; SAM002564218
CPD000058466; Loperamide hydrochloride; SAM002564218
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 4.88 | 12.85 | -54.69 | 2 | 4 | 1 | 45 | 478.056 | 7 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
MP | 223 | TCI |
ALOGPS_SOLUBILITY | 8.60e-04 g/l | DrugBank-approved |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
therap | Ca channel blocker | MicroSource Spectrum |
Therapy | Meperidine congener which binds to opioid receptors; Ca2+ channel antagonist | SMDC Iconix |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : L-5907; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER; 1 hydrogen chloride | NIH Clinical Collection via PubChem |
Target | Opioid Receptor | Selleck Chemicals |
Reactome Database Links | REACT_13765 | ChEBI |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: L-5907; SALT: 1 hydrogen chloride; SUPPLIER_COMMENTS: WHITE POWDER | NIH Clinical Collection via PubChem |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
OPRD-1-E | Delta Opioid Receptor (cluster #1 Of 3), Eukaryotic | Eukaryotes | 50 | 0.30 | Binding ≤ 10μM |
OPRM-1-E | Mu-type Opioid Receptor (cluster #1 Of 4), Eukaryotic | Eukaryotes | 1 | 0.37 | Binding ≤ 10μM |
SCN1A-2-E | Sodium Channel Protein Type I Alpha Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 270 | 0.27 | Binding ≤ 10μM |
SCN2A-1-E | Sodium Channel Protein Type II Alpha Subunit (cluster #1 Of 2), Eukaryotic | Eukaryotes | 270 | 0.27 | Binding ≤ 10μM |
SCN3A-2-E | Sodium Channel Protein Type III Alpha Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 270 | 0.27 | Binding ≤ 10μM |
SCN8A-2-E | Sodium Channel Protein Type VIII Alpha Subunit (cluster #2 Of 2), Eukaryotic | Eukaryotes | 270 | 0.27 | Binding ≤ 10μM |
OPRD-1-E | Delta Opioid Receptor (cluster #1 Of 1), Eukaryotic | Eukaryotes | 156 | 0.28 | Functional ≤ 10μM |
OPRM-1-E | Mu Opioid Receptor (cluster #1 Of 2), Eukaryotic | Eukaryotes | 58 | 0.30 | Functional ≤ 10μM |
Z50466-1-O | Trypanosoma Cruzi (cluster #1 Of 8), Other | Other | 3000 | 0.23 | Functional ≤ 10μM |
Z50512-1-O | Cavia Porcellus (cluster #1 Of 7), Other | Other | 489 | 0.26 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
OPRD_RAT | P33533 | Delta Opioid Receptor, Rat | 50.1 | 0.30 | Binding ≤ 1μM |
OPRM_RAT | P33535 | Mu Opioid Receptor, Rat | 0.16 | 0.40 | Binding ≤ 1μM |
OPRM_HUMAN | P35372 | Mu Opioid Receptor, Human | 0.53 | 0.38 | Binding ≤ 1μM |
SCN1A_HUMAN | P35498 | Sodium Channel Protein Type I Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 1μM |
SCN2A_HUMAN | Q99250 | Sodium Channel Protein Type II Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 1μM |
SCN3A_HUMAN | Q9NY46 | Sodium Channel Protein Type III Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 1μM |
SCN8A_HUMAN | Q9UQD0 | Sodium Channel Protein Type VIII Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 1μM |
OPRD_RAT | P33533 | Delta Opioid Receptor, Rat | 50.1 | 0.30 | Binding ≤ 10μM |
OPRM_HUMAN | P35372 | Mu Opioid Receptor, Human | 0.53 | 0.38 | Binding ≤ 10μM |
OPRM_RAT | P33535 | Mu Opioid Receptor, Rat | 0.16 | 0.40 | Binding ≤ 10μM |
SCN1A_HUMAN | P35498 | Sodium Channel Protein Type I Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 10μM |
SCN2A_HUMAN | Q99250 | Sodium Channel Protein Type II Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 10μM |
SCN3A_HUMAN | Q9NY46 | Sodium Channel Protein Type III Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 10μM |
SCN8A_HUMAN | Q9UQD0 | Sodium Channel Protein Type VIII Alpha Subunit, Human | 270 | 0.27 | Binding ≤ 10μM |
Z50512 | Z50512 | Cavia Porcellus | 488.9 | 0.26 | Functional ≤ 10μM |
OPRD_HUMAN | P41143 | Delta Opioid Receptor, Human | 156 | 0.28 | Functional ≤ 10μM |
OPRM_HUMAN | P35372 | Mu Opioid Receptor, Human | 58 | 0.30 | Functional ≤ 10μM |
Z50466 | Z50466 | Trypanosoma Cruzi | 3000 | 0.23 | Functional ≤ 10μM |
Description | Species |
---|---|
Xenobiotics |
Description | Species |
---|---|
G alpha (i) signalling events | |
G-protein activation | |
Interaction between L1 and Ankyrins | |
Opioid Signalling | |
Peptide ligand-binding receptors |